# Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer

> **NCT03480152** · PHASE1,PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 5 (actual)

## Conditions studied

- Melanoma
- Colon Cancer
- Gastrointestinal Cancer
- Genitourinary Cancer
- Hepatocellular Cancer

## Interventions

- **BIOLOGICAL:** National Cancer Institute (NCI)-4650, a messenger ribonucleic acid (mRNA)-based, Personalized Cancer Vaccine

## Key facts

- **NCT ID:** NCT03480152
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-05-18
- **Primary completion:** 2019-06-25
- **Final completion:** 2019-11-05
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** slow accrual
- **Last updated:** 2020-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03480152

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03480152, "Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03480152. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*